Development of stable liquid glucagon formulations for use in artificial pancreas

Journal of Diabetes Science and Technology

Volumn 9, Issue 1, 2015, Pages 8-16

  Pohl, Roderike ^a   Li, Ming ^a   Krasner, Alan ^a   De Souza, Errol ^a  

^a Biodel Inc   (United States)

Author keywords

artificial pancreas; bihormonal pump; liquid glucagon; stabilized glucagon

Indexed keywords

GLUCAGON; GLUCOSE; INSULIN; SOLUTION AND SOLUBILITY;

ANIMAL MODEL; ARTICLE; ARTIFICIAL PANCREAS; COMPARATIVE STUDY; CONTROLLED STUDY; DIABETES MELLITUS; DOG; DRUG DEGRADATION; DRUG FORMULATION; DRUG STABILITY; DRUG STORAGE; EVALUATION STUDY; IN VIVO STUDY; INSULIN PUMP; NONHUMAN; PH; PIG; SHELF LIFE; ADMINISTRATION AND DOSAGE; ANIMAL; CHEMISTRY; DEVICES; DIABETES MELLITUS, EXPERIMENTAL; DIABETES MELLITUS, TYPE 1; DRUG DELIVERY SYSTEM; FEMALE; HUMAN; MALE; PATHOLOGY; PROCEDURES; SOLUTION AND SOLUBILITY;

ANIMALS; DIABETES MELLITUS, EXPERIMENTAL; DIABETES MELLITUS, TYPE 1; DOGS; DRUG DELIVERY SYSTEMS; DRUG STABILITY; FEMALE; GLUCAGON; HUMANS; MALE; PANCREAS, ARTIFICIAL; PHARMACEUTICAL SOLUTIONS; SWINE;

EID: 84929762280     PISSN: None     EISSN: 19322968     Source Type: Journal    
DOI: 10.1177/1932296814555541     Document Type: Article

References (13)

1. Haymond MW, Schreiner B. Mini-dose glucagon rescue for hypoglycemia in children with type 1 diabetes. Diabetes Care. 2001;24(4):643-645
2. Jacobs PG, Youssef JE, Castle J, et al. Automated control of an adaptive bi-hormonal, dual-sensor artificial pancreas and evaluation during inpatient studies. IEEE Trans Biomed Eng. 2014;61:2569-2581
3. Russell SJ, El-Khatib FH, Sinha M, et al. Outpatient glycemic control with a bionic pancreas in type 1 diabetes [published online ahead of print June 15, 2014]. N Engl J Med.
4. Cersosimo E, Cummins MJ, Kinzel JH, et al. A phase 2 comparative safety PK/PD study of stable nonaqueous glucagon (G-Pen) vs. Lilly glucagon for treatment of severe hypoglycemia. Diabetes. 2014;63(suppl 1A):LB1
5. USP 37-NF 32. Official monographs. Glucagon for injection. May 1, 2014 3158-3159
6. USP 37-NF 32. Biological tests. (123) Glucagon bioidentity tests. May 1, 2014. 127-129
7. Morris TS, Singer R, Ambrose MR, Hauck WW. Biological potency assays are key to assessing product consistency. BioPharm Int. 2009;22(6). Available from: http://www.biopharminternational. com.
8. Kocher K, Wiegand HJ. Toxicology and dermatology In: Balzer D, Luder H, eds. Nonionic Surfactants-Alkylpolyglucosides, Surfactant Science Series. Vol. 91. New York, NY: Marcel Dekker; 2000:365-384
9. Maggio ET. Absorption enhancing excipients in systemic nasal drug delivery. J Excipients Food Chem. 2014;5: 100-112
10. Agarwal SK, Kriel RL, Brundage RC, Ivaturi VD, Cloyd JC. A pilot study assessing the bioavailability and pharma-cokinetics of diazepam after intranasal and intravenous administration in healthy volunteers. Epilepsy Res. 2013;105:362-367
11. Steiner SS, Li M, Hauser R, Pohl R. Stabilized glucagon formulation for bihormonal pump use. J Diabetes Sci Tech-nol. 2010;4(6):1332-1337
12. Sasaki K, Dockerill S, Adamiak D, Tickle I, Blundell T. X-ray analysis of glucagon and its relationship to receptor binding. Nature. 1975;257:751-756
13. Chou P, Fasman G. The conformation of glucagon: predictions and consequences. Biochemistry. 1975;14(11): 2536-2541